loading page

Effects of Combination of SGLT-2 Inhibitor and GLP-1 Receptor Agonist on Renal Outcome in T2D with GFR below 30 and Macroalbuminuria : A Case Series
  • Nitesh Kuhadiya,
  • Israa Mahmood
Nitesh Kuhadiya
Renown Health
Author Profile
Israa Mahmood
Renown Health
Author Profile

Abstract

We hypothesized that the combination therapy of SGLT-2(Sodium-glucose co-transporter-2)inhibitor and Glucagon-like peptide-1 receptor agonist(GLP-1RA) provide renal protection in adults with T2D with estimated GFR (eGFR) below 30ml/minute/1.73 m2. We hereby describe four consecutively treated high renal risk patients with T2D with eGFR between 21 to 30ml/minute/1.73m2.

Peer review status:ACCEPTED

23 Nov 2020Submitted to Clinical Case Reports
26 Nov 2020Submission Checks Completed
26 Nov 2020Assigned to Editor
05 Dec 2020Reviewer(s) Assigned
13 Dec 2020Review(s) Completed, Editorial Evaluation Pending
09 Jan 2021Editorial Decision: Revise Minor
20 Jan 20211st Revision Received
22 Jan 2021Submission Checks Completed
22 Jan 2021Assigned to Editor
22 Jan 2021Review(s) Completed, Editorial Evaluation Pending
25 Jan 2021Reviewer(s) Assigned
18 Feb 2021Editorial Decision: Accept